Alaunos publishes investor presentation on ALN1003 preclinical data

Alaunos

Alaunos

TCRT

0.00
  • Alaunos published a non-confidential investor presentation summarizing integrated non-GLP ALN1003 data from two diet-induced obese mouse studies.
  • Slides highlight weight loss up to 12.9% at Day 33 in a 48-day oral BID study, 30.5% at Day 14 at high dose in drinking-water dosing.
  • Dataset also shows 43% lower liver weight, lower ALT/AST/ALP, improved insulin-resistance markers, higher adiponectin, lower mean NAS scores in selected samples.
  • Presentation posted on the Investors section at https://www.alaunos.com.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alaunos Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605261101PRIMZONEFULLFEED9726542) on May 26, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.